66 results about "Intelectin" patented technology

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin αvβ3 receptor-antagonist activity and substantially reduced integrin αllbβ3 and/or α5β1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin αllbβ3 and/or α5β1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of αvβ3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.

The invention belongs to the fields of bioengineering pharmacy, protein polypeptide drugs and biomedical engineering and relates to a polypeptide having high affinity with a receptor of integrin alpha v beta3 and application of the polypeptide. The sequence of the polypeptide is Arg-Trp-Arg or Arg-Lys-Tyr. The polypeptide disclosed by the invention has higher affinity with the integrin alpha v beta3 than the traditional RGD (Arginine-Glycine-Aspartic acid) peptide and can be used in diagnosis and treatment of cancer.

A transgenic carrier with deal targets (fibroblast growth factor receptor and integrant) is composed of the polypeptide CR16 specifically linked with alkaline fibroblast growth factor receptor, the polypeptide CP9 specifically linked with integrant, and the transgenic non-virus carrier system of CR16/CP9/cationic polymer PEI/exogenous DNA. Said carrier can effectively introduce the exogenous DNA to the tumor cell line and tumor tissue with high expression of FGFRs, so suppressing the growth of tumor. It can be used to preparation of the medicine for treating tumor and other diseases.

The invention relates to a novel human derived monoclonal antibody for identifying activated integrin alpha 4 beta 7. The monoclonal antibody for specifically identifying activated integrin alpha 4 beta 7 is obtained by screening by an inventor. Based on the identification specificity, the monoclonal antibody can be used as a carrier for targeting transportation to take a medicament to positions of pathological tissues so as to fulfill an aim of treating diseases; and the monoclonal antibody also can be used as a tool for researching the activation status of the integrin alpha 4 beta 7.

The invention relates to the technical field of medicine, in particular to an exosome carrier of a target integrin alpha v beta 3 and a preparation method and application of the exosome carrier. Mononuclear suspension cells THP-1 are adopted and stimulated by PMA of the certain concentration to obtain the exosome carrier, the surface of an exosome after separating contains an RGD target molecule metalloprotease disintegrin family 15, and the target integrin receptor alpha v beta 3 can be obtained. The in-vitro releasing experiment shows that the prepared exosome can slowly release loaded chemotherapeutic medicine, and the better capacity of jointly loading genes and the chemotherapeutic medicine is achieved. In the tumor treatment process, the exosome can enhance the effects of cells of aspecificity target overexpression integrin alpha v beta 3 on tumor cells through the chemotherapeutic medicine or gene medicine, apoptosis of tumor cells is promoted, and therefore the exosome carrierforms a targeted and efficient low-toxicity bionic nanoscale delivery system of tumor treatment.

Radiolabeled cyclic polypeptides, pharmaceutical compositions comprising radiolabeled cyclic polypeptides, and methods of using the radiolabeled cyclic polypeptides. Such polypeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

The invention belongs to technical field of genes, and relates to a long non-coding RNA AY927503 and application thereof. It is proved through experiments that the long non-coding RNA AY927503 can adjust migration of human hepatocellular carcinoma cells, sulfatide can adjust migration of the human hepatocellular carcinoma cells through the long non-coding RNA AY927503, express of integrin alpha V can be adjusted, and the long non-coding RNA AY927503 can adjust migration of the cells through the integrin alpha V; it is proved through experiments that the long non-coding RNA AY927503 is mainly located in cytoplasm and also exists in cell nuclei, the long non-coding RNA AY927503 can adjust the activity of a promoter of the integrin alpha V, and the long non-coding RNA AY927503 is not combined with a transcription factor on the promoter of the integrin alpha V but is directly combined with the promoter of the integrin alpha V. According to the long non-coding RNA AY927503 and the application thereof in gene control, the long non-coding RNA AY927503 can be directly combined with the promoter of the integrin alpha V, adjust the transcriptional activity of the integrin alpha V and then influence the behavior of the cells; the long non-coding RNA AY927503 can be used for preparing a target molecule of the human hepatocellular carcinoma cells.

The invention discloses a 131I-labelled c(RGDyk)-targeting doxorubicin thermosensitive nanoliposome and its preparation and application and belongs to the field of medical technology. The structure of the 131I-labelled c(RGDyk)-targeting doxorubicin thermosensitive nanoliposome is as follows: 131I and c(RGDyk) are coupled, and c(RGDyk) is inserted through DSPE-PEG-NHS activation into the DPPC molecular layer of the liposome which wraps doxorubicin and magnetic particles. The 131I-labelled c(RGDyk)-targeting doxorubicin thermosensitive nanoliposome is mainly applied in therapeutic diagnosis and prevention of breast-cancer tumor. The advantages are as follows: by using liposome as a vector and integrin alpha v beta3 as an action target, by organically combining chemotherapy, radiotherapy and thermotherapy and through c(RGDyk) targeting action on tumor, kill rate of tumor can be raised, influence on normal body is little, and requirements on aspects of specificity, safety, effectiveness and the like are met to the greatest extent.

Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels.

The invention relates to a polypeptide-drug conjugate with a tumor directed therapy effect, and a preparation method and an application thereof. The polypeptide-drug conjugate can specifically convey PD0325901 analog to cancer cells over-expressing integrin alphavbeta3 in order to realize the directed therapy effect of tumors.

The invention relates to a chemical structure and a preparation method of a tumor imaging agent, and in particular relates to a single photon emission computed tomography (SPECT) technetium (99mTc)-labeled RGD polypeptide trimer medicine, namely 99mTc-4P-RGD3. The tumor imaging medicine is combined with an integrin alphavbeta3 in a ligand mode so as to achieve an application of imaging a tumor part. The preparation method comprises the following implementing steps: linking HYNIC-Osu to 4P-RGD3 so as to obtain a ligand HYNIC-4P-RGD3, and chelating the HYNIC in the ligand with 99mTc so as to obtain the 99mTc-4P-RGD3 tumor imaging agent. A research on animal in-vivo distribution and a tumor imaging step proves that the tumor imaging agent is relatively high in tumor uptake and lower in background uptake to normal organs in a whole body, and the definition of tumor image of the whole body is improved; a drug metabolism experimental step shows that the 99mTc-4P-RGD3, after metabolized in an animal body, can be still discharged out of the body in a prototype mode. The technetium-labeled integrin alphavbeta3 tumor imaging agent (99mTc-4P-RGD3) prepared by the technical means disclosed by the invention can be used for solving a problem of high background uptake of other technetium-labeled RGD medicines in animal body, so that the technetium-labeled RGD medicine is more suitable for the assessment of tumors in whole body.

The invention discloses integrin alpha 6 target polypeptide and application, and the sequence motif of the polypeptide is RWYXXXA. The integrin alpha 6 target polypeptide has very good affinity with integrin alpha 6, is relatively stable in vivo, and can serve as a target carrier. The integrin alpha 6 target polypeptide can be applied to molecular imaging of multiple kinds of integrin alpha 6 overexpression tumors, and has an important value in the molecular imaging of tumors. By coupling the polypeptide with a molecular imaging probe, the molecular imaging can be carried out on the multiple kinds of integrin alpha 6 overexpression tumors, and can be applied to diagnosis and screening of tumors very well.

Foot and out disease virus (FMDV) is worldwide problem. Rapid isolation, serotyping and vaccine matching of FMDV from infected animals is critical to enable the implementation of effective vaccination programs and to stop the spread of infection during outbreaks. Current virus isolation protocols use primary cells, known to be susceptible to FMDV, or baby hamster kidney cells (BHK-21) and other cell lines that are not highly sensitive to some strains of FMDV. The α_Vβ₆ integrin is a principal receptor for FMDV. We therefore transduced the porcine kidney cell line, LFBK, to stably express both the α_V and β₆ bovine integrin subunits. The LFBK-α_Vβ₆ cell line showed both β₆ expression and enhanced susceptibility to FMDV infection for at least 100 cell passages. LFBK-α_Vβ₆ cells are highly sensitive for detecting all serotypes of FMDV from experimentally infected animals, including the porcinophillic strain O/TAW/97 and are thus a sensitive tool for FMDV isolation.